Targeted therapies are an important part of the melanoma treatment arsenal, but where do they fit within the standard of care?

Genomic profiling showed patients with African ancestry had fewer actionable mutations and were less likely to qualify for immunotherapy.

REGN5459 had decreased binding affinity to T cells, resulting in an encouraging side effect profile and efficacy.

The Pragmatica-Lung Study, with fewer and simpler eligibility criteria, will test whether Cyramza plus Keytruda improves survival.

Patients who received atezolizumab (Tecentriq) plus bevacizumab (Avastin) had a 28% lower risk of cancer recurrence or death.

Research on metastatic melanoma suggests it may be possible to prevent some cancers from ever becoming resistant to targeted therapies.

The studies point to the promise of a targeted approach to acute leukemia treatment.

Treatment can improve quality of life for people with advanced breast cancer.

Patients can face escalating undisclosed costs for cancer care without knowing how it will affect their family’s finances.

The antibody-drug conjugate is now approved for patients with hormone receptor-positive/HER2-negative or triple-negative breast cancer.